Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.71 |
| ▸ | PSMD14 | O00487 | 3/20 | 0.71 |
| ▸ | PTPN22 | Q9Y2R2 | 3/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | MAP3K5 | Q99683 | 11/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | APAF1 | O14727 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220203 | 0.85 | APEX1 (0.56) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL3905770 | 0.83 | HIF1AN (0.83) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL3905768 | 0.83 | HIF1AN (0.83) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL7642796 | 0.83 | MAP3K5 (0.68) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL6791091 | 0.83 | MAP3K5 (0.68) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL26458785 | 0.83 | MEN1 (1.00) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL6798136 | 0.83 | MAP3K5 (0.72) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL6790934 | 0.82 | MAP3K5 (0.68) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL6790932 | 0.82 | MAP3K5 (0.68) | MEN1POLBMAPTKMT2AALDH1A1 | |
| SCHEMBL6791935 | 0.81 | HIF1AN (0.72) | MEN1POLBMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | claimed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | claimed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | claimed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | disclosed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MEN1 3202/4885POLB 2141/4885MAPT 1526/4885 |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MEN1 3202/4885POLB 2141/4885MAPT 1526/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | MEN1 3202/4885POLB 2141/4885MAPT 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.